Trial Profile
Open-Label Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Multiple Doses Of Topical Abi-1968 In Subjects With Anal High-Grade Squamous Intraepithelial Lesions (aHSIL)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs ABI 1968 (Primary)
- Indications Anal intraepithelial neoplasia
- Focus Adverse reactions
- Sponsors Antiva Biosciences
- 23 Jul 2019 Status changed from active, no longer recruiting to discontinued.
- 09 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 02 Jan 2019 Status changed from not yet recruiting to recruiting.